Figure 1From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison Kaplan-Meier estimate of time to progression according to type of chemotherapy associated with trastuzumab. The solid line represents patients receiving docetaxel and the dashed line those receiving vinorelbine.Back to article page